A comparative analysis of fear of cancer recurrence in patients with small renal masses: Active surveillance versus cryoablation.

IF 2.7 3区 医学 Q3 ONCOLOGY Acta Oncologica Pub Date : 2024-07-22 DOI:10.2340/1651-226X.2024.40418
Rasmine Bak, Theresa Junker, Jørgen B Jensen, Tau Pelant, Rikke N Haase, Robert Zachariae, Tommy K Nielsen
{"title":"A comparative analysis of fear of cancer recurrence in patients with small renal masses: Active surveillance versus cryoablation.","authors":"Rasmine Bak, Theresa Junker, Jørgen B Jensen, Tau Pelant, Rikke N Haase, Robert Zachariae, Tommy K Nielsen","doi":"10.2340/1651-226X.2024.40418","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>The aim of this study was to evaluate and compare the fear of cancer recurrence (FCR) in patients diagnosed with a small renal mass (SRM) and managed with either active surveillance (AS) or minimal invasive renal cryoablation (CA).</p><p><strong>Patients/material and methods: </strong>A total of 398 patients with SRMs (263 AS and 135 CA patients) were retrospectively identified across three institutions and invited to complete the Fear of Cancer Recurrence-Short Form (FCRI-SF) questionnaire.</p><p><strong>Results: </strong>No statistically significant differences in FCRI-SF score were observed between the AS (mean = 10.9, standard deviation [SD] = 6.9) and CA (mean = 10.2, SD = 7.2) (p = 0.559) patients, with the mean scores of both groups being below the suggested clinically significant cut-off of 16. A total of 25% of AS and 28% of CA patients reported sub-clinical or clinical levels of FCR (FCRI-SF score > 16). Within the AS group, a weak negative association between FCR severity and age was observed (r = -0.23, p = 0.006), and a statistically significant difference in FCRI-SF score between patients aged more or less than 73 years (p = 0.009).</p><p><strong>Interpretation: </strong>FCR levels were comparable between AS and CA patients, suggesting that treatment decisions should prioritise clinical factors. Up to 28% of AS and CA patients report clinically significant FCR, highlighting the importance of considering the possibility of FCR, especially in younger patients.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2024.40418","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: The aim of this study was to evaluate and compare the fear of cancer recurrence (FCR) in patients diagnosed with a small renal mass (SRM) and managed with either active surveillance (AS) or minimal invasive renal cryoablation (CA).

Patients/material and methods: A total of 398 patients with SRMs (263 AS and 135 CA patients) were retrospectively identified across three institutions and invited to complete the Fear of Cancer Recurrence-Short Form (FCRI-SF) questionnaire.

Results: No statistically significant differences in FCRI-SF score were observed between the AS (mean = 10.9, standard deviation [SD] = 6.9) and CA (mean = 10.2, SD = 7.2) (p = 0.559) patients, with the mean scores of both groups being below the suggested clinically significant cut-off of 16. A total of 25% of AS and 28% of CA patients reported sub-clinical or clinical levels of FCR (FCRI-SF score > 16). Within the AS group, a weak negative association between FCR severity and age was observed (r = -0.23, p = 0.006), and a statistically significant difference in FCRI-SF score between patients aged more or less than 73 years (p = 0.009).

Interpretation: FCR levels were comparable between AS and CA patients, suggesting that treatment decisions should prioritise clinical factors. Up to 28% of AS and CA patients report clinically significant FCR, highlighting the importance of considering the possibility of FCR, especially in younger patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对肾脏小肿块患者癌症复发恐惧的比较分析:主动监测与冷冻消融术
背景和目的:本研究旨在评估和比较确诊为小肾肿块(SRM)并接受积极监测(AS)或微创肾冷冻消融术(CA)治疗的患者对癌症复发的恐惧(FCR):对三家机构的398名SRM患者(263名AS患者和135名CA患者)进行回顾性鉴别,并邀请他们填写癌症复发恐惧简表(FCRI-SF)问卷:AS(平均分=10.9,标准差[SD]=6.9)和CA(平均分=10.2,标准差=7.2)患者的FCRI-SF得分差异无统计学意义(P=0.559),两组患者的平均分均低于建议的具有临床意义的临界值16分。共有 25% 的 AS 和 28% 的 CA 患者报告了亚临床或临床水平的 FCR(FCRI-SF 评分 > 16)。在强直性脊柱炎组中,观察到 FCR 严重程度与年龄之间存在微弱的负相关(r = -0.23,p = 0.006),年龄大于或小于 73 岁的患者之间的 FCRI-SF 评分差异具有统计学意义(p = 0.009):AS和CA患者的FCR水平相当,这表明治疗决定应优先考虑临床因素。高达28%的AS和CA患者报告有临床意义的FCR,强调了考虑FCR可能性的重要性,尤其是在年轻患者中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Oncologica
Acta Oncologica 医学-肿瘤学
CiteScore
4.30
自引率
3.20%
发文量
301
审稿时长
3 months
期刊介绍: Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.
期刊最新文献
Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas. Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. Classic Kaposi sarcoma: Diagnostics, treatment modalities, and genetic implications - A review of the literature. Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study. Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1